← Back to the full Peptide Guide overview
Important Disclaimer — Read Before Using This Page
This information is not intended for use by unlicensed individuals or by licensed professionals who lack adequate training and experience in assessing patients for peptide or hormone therapy. All clinical decisions and dosing must be made in consultation with a licensed, experienced physician and a licensed, experienced compounding pharmacist, and should be supported by published clinical studies.
The information presented here has been compiled using Artificial Intelligence, statements from videos and websites by apparent qualified professionals, and available published research. We strongly encourage exhaustive independent research before considering any therapy. Anyone starting a medication they have never taken before should take an extremely conservative approach.
Nothing on this page or in these videos should be taken as medical advice. These materials are provided only to help begin your research. All dosing and treatment decisions should be made between you and your medical providers after proper evaluation. We are not affiliated with any of the doctors whose videos appear on this page.
IGF-1 LR3 Investigational Compounded
Category: Insulin-Like Growth Factor-1 — Muscle & Recovery
How it works. IGF-1 LR3 is a synthetic long-acting analog of insulin-like growth factor-1. Unlike sermorelin, tesamorelin, or CJC-1295/ipamorelin, it does not stimulate the pituitary to produce a controlled downstream signal. It delivers an IGF-1-like anabolic signal directly to tissues, with reduced binding to IGF-binding proteins and a dramatically longer systemic half-life. That means the body's normal regulatory brakes are bypassed—there is no feedback shutoff, no pulsatility, and sustained direct anabolic signaling at the tissue level. That is why bodybuilders love it, and it is exactly why responsible physicians think carefully before prescribing it.
Regulatory status. IGF-1 LR3 is not FDA-approved . The only FDA-approved IGF-1-class therapy is mecasermin, which is unmodified recombinant IGF-1 approved for narrow pediatric indications of severe primary IGF-1 deficiency.
Why to be cautious. Because IGF-1 shares structural homology with insulin, hypoglycemia is a real risk. Because there is no pituitary feedback brake, IGF-1 elevation can be sustained—and sustained IGF-1 elevation is epidemiologically associated with increased risk of several cancers. Insulin resistance can develop with chronic exposure. Acromegalic soft-tissue effects—joint pain, edema, organomegaly, and facial bone changes—can occur at high exposure. WADA-tested athletes will fail drug testing. There are no completed human RCTs. If a physician does prescribe it, expect exhaustive documentation, cancer screening, glucose monitoring, and strict cycling protocols.
Recommended Videos
Dr. Jay Campbell — Tiger Fitness — IGF-1 LR3: The Ultimate Peptide for Muscle Growth & Fat Loss
Dr. Dwayne Jackson — IFBB AMA — IGF-1 LR3 vs GH Peptides — The Battle Between Performance & Risk
Dr. Greg Jones — IGF-1 LR3: What Happens to Your BODY When You Use It?
Video Sources & Independence
The videos linked on this page are provided solely for educational purposes. None of the physicians or channels featured are sponsored by, affiliated with, or compensated by NJ Weight Loss & Preventive Care Clinics, its physicians, or any individuals associated with our practice. We have selected these videos because they offer thoughtful, evidence-based discussion of mechanisms and clinical considerations. Viewers should evaluate all sources independently.
← Back to the full Peptide Guide overview · Peptide Dosing Reference →